BioCentury | Mar 10, 2018
Product Development

Virtual leap

Novartis AG’s decision to expand a collaboration with mobile technology and clinical trials management company Science 37 Inc. fits squarely within CEO Vasant Narasimhan’s oft-stated plans to use digital health to speed drug development. The...
BC Week In Review | Jan 13, 2014
Company News

Teva, Pfizer sales and marketing update

Teva launched an authorized generic of Pfizer's Detrol LA tolterodine ER in the U.S. Detrol LA, an extended-release muscarinic receptor antagonist, is approved to treat overactive bladder with symptoms of urge urinary incontinence, urgency and...
BioCentury | Dec 16, 2013
Strategy

Out in the cold

New excluded drugs lists devised by pharmacy benefits managers are raising the hurdle for reimbursement of drugs the PBMs' pharmacy and therapeutics committees consider to be clinically equivalent to cheaper drugs. Drugs that are not...
BC Week In Review | Sep 17, 2012
Company News

Mylan, Pfizer genitourinary news

Pfizer and Mylan settled a June 2010 patent suit filed in the U.S. District Court for the District of New Jersey claiming that Mylan's ANDA for a generic version of Pfizer's overactive bladder (OAB) drug...
BC Week In Review | Aug 13, 2012
Clinical News

Toviaz fesoterodine: Phase IV data

A double-blind, placebo-controlled, international Phase IV trial in 642 patients with OAB who had a suboptimal response to Detrol LA tolterodine ER showed that once-daily Toviaz significantly reduced the number of urge urinary incontinence episodes...
BC Week In Review | Jul 16, 2012
Clinical News

Detrol LA tolterodine ER: Phase IV discontinued

Pfizer said it discontinued enrollment in the double-blind, placebo-controlled, U.S. Phase IV REMOTE trial evaluating daily 4 mg Detrol LA after the enrollment rate did not meet its expectations. The pharma said the trial enrolled...
BC Week In Review | Jun 27, 2011
Clinical News

Detrol LA tolterodine ER: Phase IV started

Pfizer began the double-blind, placebo-controlled, U.S. Phase IV REMOTE trial to evaluate daily 4 mg Detrol LA tolterodine ER in about 600 patients. The trial will use mobile phones and web-based technology to collect data...
BC Week In Review | May 23, 2011
Clinical News

THVD-201: Phase II started

TheraVida began a double-blind, placebo-controlled, crossover, international Phase II trial in 120 female patients to compare 2 mg THVD-201 vs. 2 mg Detrol LA tolterodine tartrate for 16 weeks. Patients will have the option to...
BC Week In Review | Apr 4, 2011
Clinical News

THVD-201: Phase I data

An Australian Phase I trial in 17 healthy volunteers showed that THVD-201 was safe and improved salivary output and related dry mouth side effects compared to Detrol LA tolterodine from Pfizer Inc. (NYSE:PFE, New York,...
BC Week In Review | May 4, 2009
Clinical News

Detrol LA tolterodine ER: Post-marketing study data

In a study of 156 patients, switching from branded anticholinergic medications to generic oxybutynin resulted in a decrease in efficacy and safety after 8 weeks. Specifically, in female patients (n=87), average urination frequency increased from...
Items per page:
1 - 10 of 25